Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the most profitable new stocks to buy now. On July 18, it was reported that ...

Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) ...

Researchers conducted a retrospective study published in July 2025 issue of Journal of Clinical Oncology to evaluate risk-adaptive, surgery– and radiotherapy-free management following neoadjuvant ...

That being said, we’re here with a list of the 10 most profitable new stocks to buy now. We sifted through the Finviz stock screener to compile a list of the top companies that went public in the last ...

These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

Scancell Holdings plc (AIM: SCLP), the developer of Immunobody ® and Moditope ® active immunotherapies to treat cancer, announces further positive data from the ongoing Phase 2 SCOPE trial of ...

Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Phase 3 data support “changing the current standard of care to now include neoadjuvant and adjuvant pembrolizumab,” according to Ravindra Uppaluri, MD, PhD.